法莫替丁(Famotidine,FAM)是继西咪替丁(Cimetidine,CIM)和雷尼替丁(Ranitidine,RAN)之后第三个治疗消化性溃疡的 H_2受体拮抗剂,1984年由日本March 公司在里斯本世界胃肠学会议上首次推出,国内最近已合成并将投入生产。药代动力学 FAM 主要经口服途径给药,生物利用度为40%左右,峰浓度出现时间为口服后2～4h,作用持续10～12h,半衰期3.7h,静脉注射效果比口服强1倍。在临 Famotidine (FAM) is the third H 2 receptor antagonist to treat peptic ulcer after Cimetidine (CIM) and Ranitidine (RAN). In 1984, Japan’s March The company was first introduced at the World Gastroenterology Conference in Lisbon and has recently been synthesized and will be put into production in the country. Pharmacokinetics FAM mainly by oral administration, bioavailability of about 40%, peak concentration occurs after oral administration 2 ~ 4h, the role of sustained 10 ~ 12h, half-life of 3.7h, intravenous injection of 1 times stronger than oral. Pro in progress